AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Optomed Oyj

Declaration of Voting Results & Voting Rights Announcements Sep 25, 2023

3329_dva_2023-09-25_0ed7c13c-0180-4a96-a82f-0fa8de03f1ab.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Disclosure 437523

Optomed Oyj - Total number of voting rights and capital

New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register

OPTOMED PLCSTOCK EXCHANGE RELEASE25 September 2023, at 10.00 a.m. EEST New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register A total of 1,589,042 new shares subscribed for in Optomed Plc's directed share issue have been registered into the Finnish Trade Register today, on 25 September 2023. After the registration of the new shares, the company will have 18,130,397 shares in total of which 353,973 shares in treasury. The new shares produce the right to dividends and other distribution of assets as well as other shareholder rights as of this registration date. The new shares will be admitted to trading on the official list of Nasdaq Helsinki Ltd today. Optomed Plc Further enquiries Sakari Knuutti, CFO, Optomed Plc, [email protected] Distribution Nasdaq Helsinki Ltd Principal media www.optomed.com Optomed in Brief Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

Talk to a Data Expert

Have a question? We'll get back to you promptly.